ストックスクリーナーアプリを入手
1.86
3.91%
0.07
アフターアワーズ：
1.87
0.01
+0.54%
前日終値:
$1.79
開ける：
$1.82
24時間の取引高:
130.97K
Relative Volume:
1.07
時価総額：
$27.68M
収益：
$486.00K
当期純損益:
$-28.43M
株価収益率:
-0.6598
EPS:
-2.8189
ネットキャッシュフロー:
$-26.75M
1週間 パフォーマンス:
+2.20%
1か月 パフォーマンス:
+8.14%
6か月 パフォーマンス:
-22.50%
1年 パフォーマンス:
-20.85%
1日の値動き範囲:
$1.77
$1.89
1週間の範囲:
$1.75
$1.89
52週間の値動き範囲:
$1.44
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
名前
Vyne Therapeutics Inc
セクター
電話
800-775-7936
住所
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
VYNE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
1.86 | 27.68M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | 開始されました | BTIG Research | Buy |
| 2021-12-06 | 再開されました | H.C. Wainwright | Buy |
Vyne Therapeutics Inc (VYNE) 最新ニュース
Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN
Invesco Canada announces cash distributions for its ETFs - The Globe and Mail
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan
VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World
VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com
VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World
HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times
Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan
VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq
Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times
Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan
VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia
Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance
VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World
Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga
VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ
VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - Yahoo Finance
VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa
VYNE stock soars to 52-week high, touches $3.43 - Investing.com
VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance
VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times
Vyne Therapeutics Inc (VYNE) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):